on INNATE PHARMA (EPA:IPH)
Innate Pharma's IPH6501 Shows Potential in Lymphoma Treatment
Innate Pharma presented promising preclinical data for IPH6501 at the 2025 European Hematology Association Congress. IPH6501, an ANKET® targeting CD20, has demonstrated significant antitumor activity in vitro against Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) patient samples. Furthermore, in vivo models indicate enhanced efficacy when combined with R-CHOP, the current standard care for these lymphomas.
The current Phase 1/2 study investigates IPH6501's potential in relapsed or refractory B-cell non-Hodgkin lymphoma. Early results suggest its capability to improve outcomes in rituximab-resistant scenarios and offer new treatment avenues. This underscores the therapeutic promise of IPH6501 in enhancing existing lymphoma therapies.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INNATE PHARMA news